Physician profile
Michaela E Renich
NPI 1841229127
$1,011.49
in general payments reported to CMS, 2019-2025
14 companies · $38.27 in 2025
The $38.27 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.78 · 2020: $14.29 · 2021: $22.99 · 2022: $223 · 2023: $337 · 2024: $335 · 2025: $38.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.31 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $201.72 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $172.78 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $129.13 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $50.20 | 2024-2025 | |
| Astellas Pharma US INC | $45.87 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.10 | 2022-2024 | Xifaxan |
| Amgen INC. | $41.10 | 2022-2023 | Prolia, Evenity |
| Sumitomo Pharma America, INC. | $24.14 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $22.07 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.22 | 2024 | Rexulti |
| Organon LLC | $20.18 | 2025 | Nexplanon |
| Cranial Technologies, INC | $17.44 | 2023 | Doc Band |
| Abbvie INC. | $14.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Renich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.